“Cheaper and better”: Societal cost savings and budget impact of changing from systemic to intralesional pentavalent antimonials as the first-line treatment for cutaneous leishmaniasis in Bolivia

Daniel Eid RodríguezMiguel San SebastiånAnni‐Maria Pulkki‐Brännström2026-03-222026-03-22201910.1371/journal.pntd.0007788https://doi.org/10.1371/journal.pntd.0007788https://andeanlibrary.org/handle/123456789/45795Citaciones: 15The results of this study support a shift to ILPA as the first-line treatment for CL in Bolivia and possibly in other South American countries.enMedicineEconomic shortageChristian ministryCutaneous leishmaniasisNeglected tropical diseasesBusinessEnvironmental healthLeishmaniasis“Cheaper and better”: Societal cost savings and budget impact of changing from systemic to intralesional pentavalent antimonials as the first-line treatment for cutaneous leishmaniasis in Boliviaarticle